We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...

which DexCom previously spoke about. BofA, which has a Buy rating and $90 price target on the shares, would use the stock move as a buying opportunity, as it does not see the news having an impact ...

The list is sorted in ascending order of hedge fund sentiment ... It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time ...

The FDA has cleared Dexcom’s Stelo ... sites at knockdown prices, raising questions about their quality and/or authenticity. Dexcom has said it intends to launch Stelo in the summer, but has ...